NEW BRUNSWICK (dpa-AFX) - Nanobiotix (NBTX) announced the presentation of Part 1 data from the Johnson & Johnson-sponsored CONVERGE study, a randomized Phase 2 clinical trial evaluating the potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage III inoperable non-small cell lung cancer (NSCLC), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting.
Early findings indicated that intratumoral and intranodal injection of JNJ-1900 (NBTXR3) is both feasible and safe for patients with stage III unresectable NSCLC. Importantly, initial efficacy responses observed in seven patients who completed the full treatment regimen-which included concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and consolidation with durvalumab-are encouraging.
Among these patients, the overall response rate (ORR) reached 85.7%, with six out of seven showing positive outcomes. The complete response rate (CRR) was 57.1%, with four patients achieving complete remission, while the disease control rate (DCR) was 100%, as all seven patients experienced disease stabilization or improvement. Notably, the absence of progressive disease and the deepening of responses over time suggest the potential for durable, long-term benefit.
NBTX closed Friday's regular trading at $51.50 or $3.57 or 6.48%.
For More Such Health News, visit rttnews.com
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
